The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Ferring; ipsen; Janssen-Cilag; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen-Cilag; Sanofi
Speakers' Bureau - Astellas Pharma; Astellas Pharma; AstraZeneca; Janssen-Cilag; Janssen-Cilag
Research Funding - AstraZeneca; AstraZeneca (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi
Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Exelixis; Exelixis; FORMA Therapeutics; GoodRx; Janssen; Merck; Myovant Sciences; Novartis; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Noel W. Clarke
No Relationships to Disclose
 
Antoine Thiery-Vuillemin
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Roche
 
Mototsugu Oya
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Bayer
Research Funding - Astellas Pharma
 
Giuseppe Procopio
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb (BMS); Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer
 
Juliana Janoski De Menezes
No Relationships to Disclose
 
Gustavo Colagiovanni Girotto
Honoraria - MSD Oncology
Speakers' Bureau - MSD Oncology
Research Funding - BMS Brazil (Inst); MSD Oncology (Inst)
 
Pooja Ghatalia
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)
 
Franco Nole
No Relationships to Disclose
 
Omar Din
Speakers' Bureau - Advanced Accelerator Applications
 
Philipp Spiegelhalder
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly
Research Funding - AstraZeneca; Janssen; Lilly
 
Ivan Mincik
No Relationships to Disclose
 
Robbert J. van Alphen
No Relationships to Disclose
 
Nicolaas Lumen
Research Funding - Bayer (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst)
 
Christian Hosius
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Diansong Zhou
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Laura Barker
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Melanie Elizabeth Dujka
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)